On the heels of a report from the World Health Organization (WHO) that warns about "superbugs" making inroads across the globe, Cubist Pharmaceuticals Inc. popped the lid off phase III data with its ceftolozane/tazobactam combo antibiotic at the 24th European Congress of Clinical Microbiology and Infectious Diseases.